Trilaciclib in Patients Receiving Sacituzumab Govitecan-hziy for Triple Negative Breast Cancer
Clinical trial NCT05113966 · TERMINATED
Trial details
- NCT number
- NCT05113966
- Sponsor
- G1 Therapeutics, Inc.
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-12-08
- Primary completion
- 2023-11-10
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.